GlaxoSmithKline teams up with Sanofi for a Covid-19 vaccine. Are its shares worth considering?

GlaxoSmithKline has teamed up with Sanofi to develop a vaccine for Covid-19. It’s good news for everyone, but will it be good news for the GSK share price?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has teamed up with French pharmaceuticals company Sanofi to develop a vaccine for Covid-19. It’s good news for everyone, but will it be good news for the GlaxoSmithKline share price?

If there is one business activity that public opinion doesn’t like right now, it’s profiteering. Happily, this is not what GlaxoSmithKlin is doing.

I think GlaxoSmithKline shares look tempting. Not specifically because GSK may help us defeat the virus, but because of what this announcement tells us about the company.

CEO Emma Walmsley has said the company won’t profit from any resulting vaccine during the pandemic. Instead it would use the revenue to fund a ramp-up in manufacturing.

This tells us the company is well placed for the world that will emerge once this crisis is finally over.

The deal

The arrangement entails combining the Sanofi’s DNA technology, which it uses to manufacture flu vaccines, with GSK’s expertise in adjuvant technology. This technology leads to a much stronger immune system reaction, creating more antibodies.

The adjuvant technology means a much lower dosage is required for a vaccine to be effective. As a result, vaccine production can be increased more rapidly.

It is extremely unusual for pharmaceutical companies to collaborate in this way. Walmsley called it “unprecedented“. She also referred to the remarkable speed with which the two companies plan to mass produce a vaccine. They expect the vaccine to be available in the second half of next year. It normally takes many years, even as long as a decade, to be able to mass produce a new vaccine.

That’s modern technology for you. If the Covid-19 pandemic had occurred a few years ago, there would have been no hope of developing a vaccine so fast.

Post Covid-19

I believe that once this crisis is finally at an end, the world will seem like a different place with very different priorities.

There will also be much greater awareness of the dangers from disease. Covid-19 is the third major coronavirus this century. The pressures created by climate change and over-population is some regions means there will probably be more.

Furthermore, with antibiotics losing their effectiveness, I expect to see renewed efforts to develop new antibiotics. GlaxoSmithKline is proving that its outstanding expertise will be invaluable in this new era.

Foolish bottom line

Glaxo’s share price has fallen around 14% from this year’s peak price. In general, I think the markets are underestimating the long-term economic effects of this crisis. GlaxoSmithKline, however, is one of the few companies that I think is well poised for the post Covid-19 era. Recent falls in the share price push its forward price-to-earnings ratio down to around 13. At the current share price, forecast dividends are 5.3%. However, I don’t think the share price is reflective of this upside potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Michael Baxter has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 140% and rocketing out of the FTSE 250! Is it too late for me to buy this red-hot stock?

Miniature war games hero Games Workshop has outgrown the FTSE 250 and is hammering at the door of the UK's…

Read more »

Investing Articles

If I invest £10,000 in Taylor Wimpey shares, how much passive income will I receive?

Taylor Wimpey shares have fallen and are now paying a huge dividend. How much might I receive by investing a…

Read more »

Index Funds text carved in stone background
Investing Articles

Why I choose to invest in individual stocks rather than an index fund

Our writer examines the differences between stock picking and investing in index funds and why he feels there’s more to…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s the dividend forecast for Sage Group shares through to 2026!

The dividend on Sage shares has risen for 12 straight years. Can the FTSE 100 company keep its proud record…

Read more »

Happy African American Man Hugging New Car In Auto Dealership
Investing Articles

Will 2025 be make or break for this FTSE 250 stock hitting the headlines?

One of the FTSE 250's worst performers in 2024 has just issued another profit warning, but could 2025 mark the…

Read more »

Investing Articles

£3,000 invested in Greggs shares three months ago is worth this much now

Harvey Jones was on the verge of buying Greggs shares in August but decided they looked a little pricey. So…

Read more »

Investing Articles

After rising a stunning 97% is this FTSE star still my best share to buy today?

This time last year Harvey Jones declared FTSE 100 data analytics firm RELX to be the best share to buy.…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

2 top growth stocks I’m buying in December… before it’s too late

When it comes to growth stocks, Stephen Wright thinks rising prices are limiting opportunities right now. But it’s quality, not…

Read more »